Senti Biosciences Holdings, Inc. Share Price & Technical Analysis
SNTI · $0.99 (0.00%)
Healthcare / Biotechnology
$0.99
0.00%
Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various onco…
Price chart
Seasonality
May has 0 positive and 3 negative years (last 5 years shown)
0% return in May, -13% avg return in past 3 year May month.
-18% return in 2026, -89% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -9% | -10% | -11% | 13% | 0% | – | – | – | – | – | – | – | -18% |
| 25 | 22% | -30% | 13% | 3% | -6% | -32% | -23% | -12% | -7% | 43% | 10% | -55% | -73% |
| 24 | -34% | -4% | -12% | -5% | -19% | -3% | -34% | 13% | -15% | 0% | 5% | -51% | -160% |
| 23 | 29% | -18% | -23% | -18% | -14% | -29% | 34% | -25% | -37% | -38% | 59% | 47% | -34% |
| 22 | 1% | 1% | 0% | 0% | 0% | -80% | 63% | -20% | 13% | 5% | -4% | -39% | -61% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Uptrend
Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia. In addition, the company develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd. The company was formerly known as Senti Biosciences, Inc. and changed its name to Senti Biosciences Holdings, Inc. in April 2026. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$30.33M
P/E ratio
—
52W high
$3.88
52W low
$0.77
Volume
2,54,496
Beta
2.10
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Senti Biosciences Holdings, Inc. share price today?
- Senti Biosciences Holdings, Inc. (SNTI) last traded around $0.99 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does SNTI have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for SNTI. Download the app for real-time alerts.
- How can I analyze Senti Biosciences Holdings, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.